Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05171179 · ClinicalTrials.gov registry record · Phase 3
The Use of Pecs Blocks in Combination With Exparel in Breast Reconstruction Surgery
A Phase 3 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 3
- Development phase
- 60
- Enrollment target
NCT05171179 is a Phase 3 study that has completed, run by Northwestern University. The registered enrollment target is 60 participants.
The verdict
NCT05171179, a Phase 3 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 60 participants
- Enrollment target
Study Summary
This project intends to more thoroughly investigate the direct influence of Pecs blocks in the administration of Exparel, a non-opioid analgesic, in breast reconstruction surgery. The hypothesis is that this analgesic delivery method will significantly reduce negative outcomes such as post-operative pain, opioid use, and nausea while increasing positive outcomes such as post-operative physical activity.
Interventions
- DRUG Bupivacaine
- DRUG Exparel
- PROCEDURE Breast Reconstruction (Mammaplasty)
- DEVICE Pecs blocks
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2021-10-22 |
| Est. Completion | 2025-07-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05171179
The ClinicalTrials.gov registry entry for NCT05171179 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Bupivacaine is the first listed.
NCT05171179 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05171179 about?
NCT05171179 is a clinical study titled "The Use of Pecs Blocks in Combination With Exparel in Breast Reconstruction Surgery". This project intends to more thoroughly investigate the direct influence of Pecs blocks in the administration of Exparel, a non-opioid analgesic, in breast reconstruction surgery. The hypothesis is that this analgesic delivery method will significantly reduce negative outcomes such as post-operative...
What is the current status of trial NCT05171179?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2021-10-22. Estimated completion is 2025-07-01.
What interventions are being tested in trial NCT05171179?
The interventions under investigation include: Bupivacaine (DRUG), Exparel (DRUG), Breast Reconstruction (Mammaplasty) (PROCEDURE), Pecs blocks (DEVICE).
Who is sponsoring clinical trial NCT05171179?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.